Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MB710 是一种氨基苯并噻唑衍生物,是致癌 p53 突变体 Y220C 的稳定剂。MB710 与 Y220C 口袋紧密结合并稳定p53-Y220C,Kd 值为 4 μM。 MB710 在 p53-Y220C 细胞系中显示抗癌活性。
产品描述 | MB710, an aminobenzothiazole derivative, stabilizes the oncogenic p53 mutation Y220C by binding tightly to the Y220C pocket, enhancing the stability of p53-Y220C with a dissociation constant (Kd) of 4.1 μM. This compound exhibits anticancer activity in cell lines harboring the p53-Y220C mutation [1]. |
体外活性 | MB710 (0-200 μM; 72 hours) shows relatively low toxicity against all tested cell lines at concentrations up to 60 μM, while showing initial selective viability reduction at higher concentrations [1]. MB710 (72 hours) treats cancer cell lines NUGC3, NUGC4, WI38 and SW1088, with IC 50 s of 90, 120, >120, >120 μM, respectively [1]. MB710 (0-120 μM; 72 hours; HUH-7 cells) shows stronger cytotoxic effects in presence of p53-Y220C [1]. Cell Viability Assay [1] Cell Line: NUGC3 (mutant p53 Y220C), HUH-7 (mutant p53 Y220C), NUGC4 (p53 WT), HUH-6 cells (p53 WT) Concentration: 0-200 μM Incubation Time: 72 hours Result: Showed relatively low toxicity against all cell lines tested at concentrations up to 60 μM. NUGC3 was the most sensitive cell line. |
分子量 | 457.29 |
分子式 | C16H16IN3O3S |
CAS No. | 2230044-57-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MB710 2230044-57-0 MB-710 MB 710 Inhibitor inhibitor inhibit